Dermatologic Adverse Events Associated With Afatinib: An Oral ErbB Family Blocker

The document discussed the dermatologic adverse events (AEs) associated with afatinib, an oral ErbB family blocker used in cancer treatment. Common AEs included papulopustular rash, pruritus, xerosis, paronychia, and alopecia, significantly impacting patient well-being and treatment adherence. In clinical trials involving 2,078 patients, rash/acne was reported in 73% of patients, with grade 3 rash/acne in 13%. Effective management strategies, including topical and oral treatments, were essential to mitigate these AEs. Dose modifications were necessary for severe cases, and patient education on skin care was crucial. The impact of these AEs extended beyond physical discomfort, affecting patients' quality of life and treatment compliance.